Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Obesity – Epidemiology – Epidemiology Dashboard

Login to access report north_east
Contact sales account_box

Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total obesity / overweight prevalent cases for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s obesity / overweight forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of obesity / overweight and the number of new diagnoses of obesity / overweight?
  • Of all people diagnosed with obesity / overweight, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of obesity / overweight over the forecast period?

In addition to the total obesity prevalent cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following obesity / overweight subpopulations:

  • Total overweight prevalent cases
  • Total obesity prevalent cases after effective usage of GLP-1RAs
  • Drug and non-drug-eligible overweight prevalent cases
  • Severity 
  • Diagnosed and undiagnosed prevalent cases
  • Diagnosed drug and non-drug-treated obesity prevalent cases
  • Diagnosed drug and non-drug-eligible overweight prevalent cases

Note: Coverage may vary by country.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
north_east
Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
north_east
Report
Biosimilars – Current Treatment – Ophthalmology
The ophthalmology market is relatively new in the field of biosimilars: Samsung Bioepis / Biogen’s ranibizumab biosimilar, Byooviz, was the first MAb biosimilar to launch in the U.S. market in…
north_east
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
north_east
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east